No recent analyst price targets found for MOTS.
Latest News for MOTS
Vanta Commends U.S. FDA Advisory Committee Vote Recommending Inclusion of Six Peptide Substances on FDA's 503A Bulks List, Including BPC-157, TB-500 and MOTS-c
News Release Highlights: U.S. FDA Pharmacy Compounding Advisory Committee recommends the inclusion of six peptide substances, including BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, on the FDA's 503A Bulks List, representing a significant step in the FDA's ongoing regulatory review process for these peptide substances. Vanta has established a strategic operating framework supporting its contemplated U.S. peptide…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MOTS.
U.S. House Trading
No House trades found for MOTS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.